IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective open label single-arm, single-institution phase II clinical trial to
test the efficacy of neoadjuvant treatment with IXO (Irinotecan, Capecitabine [Xeloda],
Oxaliplatin) followed by chemoradiotherapy and resection in patients with resectable
non-metastatic primary rectal cancer of stage cT3-T4 N0-N2.
Phase:
Phase 2
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborators:
Hoffmann-La Roche Ottawa Regional Cancer Foundation Sanofi